TScan Therapeutics Statistics
Share Statistics
TScan Therapeutics has 56.59M
shares outstanding. The number of shares has increased by 7.05%
in one year.
| Shares Outstanding | 56.59M |
| Shares Change (YoY) | 7.05% |
| Shares Change (QoQ) | 6.03% |
| Owned by Institutions (%) | 34.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 899 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 1.79M, so 3.17% of the outstanding
shares have been sold short.
| Short Interest | 1.79M |
| Short % of Shares Out | 3.17% |
| Short % of Float | 3.83% |
| Short Ratio (days to cover) | 3.46 |
Valuation Ratios
The PE ratio is -2.67 and the forward
PE ratio is -1.06.
TScan Therapeutics's PEG ratio is
0.17.
| PE Ratio | -2.67 |
| Forward PE | -1.06 |
| PS Ratio | 120.9 |
| Forward PS | 0.5 |
| PB Ratio | 1.41 |
| P/FCF Ratio | -2.97 |
| PEG Ratio | 0.17 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for TScan Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.14,
with a Debt / Equity ratio of 0.4.
| Current Ratio | 8.14 |
| Quick Ratio | 8.14 |
| Debt / Equity | 0.4 |
| Debt / EBITDA | -0.81 |
| Debt / FCF | -0.85 |
| Interest Coverage | -36.91 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $14,080 |
| Profits Per Employee | $-637,495 |
| Employee Count | 200 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -85.55% in the
last 52 weeks. The beta is 1.06, so TScan Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.06 |
| 52-Week Price Change | -85.55% |
| 50-Day Moving Average | 1.5 |
| 200-Day Moving Average | 3.61 |
| Relative Strength Index (RSI) | 40.01 |
| Average Volume (20 Days) | 470,180 |
Income Statement
In the last 12 months, TScan Therapeutics had revenue of 2.82M
and earned -127.5M
in profits. Earnings per share was -1.14.
| Revenue | 2.82M |
| Gross Profit | 2.82M |
| Operating Income | -134.82M |
| Net Income | -127.5M |
| EBITDA | -119.74M |
| EBIT | -123.85M |
| Earnings Per Share (EPS) | -1.14 |
Full Income StatementBalance Sheet
The company has 178.69M in cash and 97.38M in
debt, giving a net cash position of 81.31M.
| Cash & Cash Equivalents | 178.69M |
| Total Debt | 97.38M |
| Net Cash | 81.31M |
| Retained Earnings | -375.1M |
| Total Assets | 332.71M |
| Working Capital | 225.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -110.82M
and capital expenditures -3.83M, giving a free cash flow of -114.65M.
| Operating Cash Flow | -110.82M |
| Capital Expenditures | -3.83M |
| Free Cash Flow | -114.65M |
| FCF Per Share | -1.02 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -4787.68% and -4527.66%.
| Gross Margin | 100% |
| Operating Margin | -4787.68% |
| Pretax Margin | -4527.66% |
| Profit Margin | -4527.66% |
| EBITDA Margin | -4252.06% |
| EBIT Margin | -4787.68% |
| FCF Margin | -4071.27% |
